To identify and repurpose rapidly, efficiently and at low cost already marketed drugs for new antiviral indication
By targeting host cellular pathways instead of viral proteins, Signia therapeutics drug candidates achieve broad-spectrum antiviral efficacy and minimize the risk of emergence of drug-resistant viruses
Signia Therapeutics approach offers intrinsic de-risking of drug discovery process, with significant cost and time reduction to validate drug candidates, with rapid transition to phase 2 clinical evaluation.
Our research strategy is based on the direct exploitation of clinical samples and the characterisation of relevant in vivo transcriptomic signatures of infections, in an innovative bedside-to-bench and bench-to-bedside approach.
Latest developments of Signia Therapeutics
Signia Therapeutic’s drug discovery platform has already demonstrated its significant potential with proofs-of-concept for several FDA-approved drugs that were validated for new anti-influenza and anti-MERS-CoV indications.
Creation of Signia Therapeutics
Signia therapeutics laureate of i-Lab 2017 Award
Entry of new Shareholders
Start of FluNext Phase 2 clinical assay
Major Licence agreement for three patents
EU H2020 seal of Excellence Award
Latest news about Signia Therapeutics - Press releases - Medias
Signia Therapeutics announces it has been invited to present company and update of development at the upcoming 6th ISIRV-AVG “Advan ...
Signia Therapeutics announces an agreement with SANOFI to evaluate potential pipeline candidates LYON, FRANCE (November 1, 2018) ...
Signia Therapeutics announces the nomination of Dr. Philippe Personne as CEO, effective as of 1st of October. Dr. Personne graduate ...
Do not hesitate to contact us!
Signia therapeutics.com - Copyright 2018. All right reserved.